GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AK-111 | AK111
Compound class:
Antibody
Comment: Gumokimab (AK111) is a humanized IgG1 anti-IL-17A monoclonal antibody [2]. It blocks pro-inflammatory cytokine secretion mediated by the IL-17/IL-17 receptor signaling pathway. Based on heavy and light chain CDR sequence matches gumokimab is likely claimed in Akeso's patent EP3805264A1, and is most probably antibody13E9 H3L2 therein [3].
|
| References |
|
1. Jiang C, Zhou H, Zhang W, Xia Y, Li B, Ni X, Wang G, Zhang W, Chen B, He Z et al.. (2023)
Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study. Dermatol Ther (Heidelb), 13 (2): 555-567. [PMID:36566344] |
|
2. Kim D, Yang S, Gill M, Babaei N, Cervantes M, Wu JJ. (2025)
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. Am J Clin Dermatol, [Epub ahead of print]. [PMID:39982633] |
|
3. Li B, XiaY, Wang ZM, Zhang P. (2021)
Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof. Patent number: EP3805264A1. Assignee: Akeso Biopharma Inc. Priority date: 24/05/2019. Publication date: 14/04/2021. |
